Ensysce Biosciences
ENSC

$0.3303

0%

Market Cap: $2.91M

About: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Employees: 8

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

10% more funds holding

Funds holding: 10 [Q1] → 11 (+1) [Q2]

7% more capital invested

Capital invested by funds: $237K [Q1] → $253K (+$16.5K) [Q2]

2.94% less ownership

Funds ownership: 9.52% [Q1] → 6.58% (-2.94%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ENSC.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ENSC published over the past 30 days

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain SAN DIEGO, CA / ACCESSWIRE / September 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has submitted to the FDA its PF614-301 protocol of the study, "A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain after Abdominoplasty". Included in the Phase 3 study is the Company's statistical analysis plan for review and input by the FDA.

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium emphasized opioid use worldwide, the current landscape for treating severe pain, including post-surgical and cancer pain treatment, and discussed Ensysce's innovative new class of opioid drug products.

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of 3,553,194 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.47 per share (or common stock equivalent in lieu thereof) in a registered direct offering. The Company also entered into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 7,203,504 shares of common stock of the Company originally issued in February 2024, having an exercise price of $1.06 per share, at a reduced exercise price of $0.47 per share.

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received Investigational Review Board ("IRB") approval of the PF614-MPAR-102 protocol, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 capsule is Co‑Administered with Nafamostat as a combination Immediate Release solution and Extended-Release Capsule Formulation in Healthy Subjects.' Ensysce has continued its collaboration with Quotient Sciences to conduct this second clinical study of MPAR using their Translational Pharmaceutics® platform.

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

~ Substantial Award Follows FDA Breakthrough Therapy Designation for PF614-MPAR ~ ~ Federal Grant Funding Awarded to Date Now at $40 Million ~ SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced receipt of a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection that received Breakthrough Therapy designation from the FDA in January 2024. Funding from this award will be available over a period of approximately three years, allowing for the completion of the Phase 1b clinical trial, PF614-MPAR-102.

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks.

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA SAN DIEGO, CA / ACCESSWIRE / August 14, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2024. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our FDA-designated Breakthrough Therapy product candidate, PF614-MPAR, is a game-changer for Ensysce as we progress to a second clinical trial, PF614-MPAR-102.

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of severe pain, including post-surgical and cancer pain treatment, and discussed potential innovative treatment options, noting the limited number of new therapeutic agents approved in the last ten years.

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Ensysce Biosciences Provides Mid-Year 2024 Update

~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~ ~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~ ~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~ SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough Therapy designation from the U.S. Food & Drug Administration (FDA). Recent clinical and development highlights: PF614: Successfully completed a PF614 End of Phase 2 meeting with the FDA, which provided guidance on strategy and design of the Phase 3 clinical program.

Ensysce Biosciences Provides Mid-Year 2024 Update

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, two leading authorities on pain, pain treatment and analgesic drug development.

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

See News Rankings